// App-Quantinova.ai

: Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation

Researchers

Presenter

  • Vincent Cottin

Principal Investigators

  • Sonia Guéguen

  • Stéphane Jouneau

  • Hilario Nunes

  • Bruno Crestani

  • Philippe Bonniaud

  • Lidwine Wemeau

  • Dominique Israel-Biet

  • Marie Chevereau

  • Isabelle Dufaure-Garé

  • Serge Amselem

  • Annick Clément

Medical Centers

  • HCL-UCBL, Lyon, France

  • Radico, Paris, France

  • CHU Rennes, Rennes, France

  • CHU d'Avicenne, Avicenne, France

  • CHU de Paris-Bichat, Paris, France

  • CHU de Dijon, Dijon, France

  • CHRU Lille, Lille, France

  • Paris HEGP, Paris, France

  • CHU de Paris-Trousseau, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved